Active Filter(s):
Details:
The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.
Lead Product(s): Aumolertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Ameile
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022